Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Nivolumab for adjuvant urothelial carcinoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Nivolumab for adjuvant urothelial carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Nivolumab for adjuvant urothelial carcinoma

New Indication: Nivolumab for adjuvant urothelial carcinoma
Study:
  • Double-blind, randomized Phase III trial (CheckMate 274)
  • Pts with muscle-invasive urothelial Ca, s/p R0 resection, with/without neoadjuvant chemo
  • Nivolumab 240 q14 (n=353) vs. placebo (n=356)
Efficacy:
  • Median DFS: 20.8 vs. 10.8 mos
  • DFS @ 6 mos: 74.9% vs. 60.3% (HR: 0.70 [0.55-0.90])
  • HR for DFS in pts with <1% PD-L1 expression: 0.82 [0.63-1.06]
Safety:
  • Grade >= 3 AEs: Increased lipase (5.1% vs. 2.6%), diarrhea (0.9% vs. 0.3%), rash (0.6% vs. none)

N Engl J Med 2021;384:2102-14.

Bajorin DF, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

https://doi.org/10.1056/NEJMoa2034442

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More